Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study
- 1 October 2003
- journal article
- clinical trial
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 1 (10) , 2119-2130
- https://doi.org/10.1046/j.1538-7836.2003.00368.x
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip ReplacementNew England Journal of Medicine, 2001
- Prevention of Venous ThromboembolismChest, 2001
- Prevention of Venous ThromboembolismChest, 1998
- Efficacy and Safety of Prolonged Thromboprophylaxis with a Low Molecular Weight Heparin (Dalteparin) after Total Hip Arthroplasty— The Danish Prolonged Prophylaxis (DaPP) StudyThrombosis Research, 1998
- A Comparison of Recombinant Hirudin with a Low-Molecular-Weight Heparin to Prevent Thromboembolic Complications after Total Hip ReplacementNew England Journal of Medicine, 1997
- Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393The Lancet, 1996
- A Comparison of Subcutaneous Low-Molecular-Weight Heparin with Warfarin Sodium for Prophylaxis against Deep-Vein Thrombosis after Hip or Knee ImplantationNew England Journal of Medicine, 1993
- Reduction in Fatal Pulmonary Embolism and Venous Thrombosis by Perioperative Administration of Subcutaneous HeparinNew England Journal of Medicine, 1988
- Is Embolic Risk Conditioned By Location of Deep Venous Thrombosis?Annals of Internal Medicine, 1981
- Roentgen Diagnosis of Venous Thrombosis in the LegArchives of Surgery, 1972